Nivalis Therapeutics
Developing a novel class of disease modifying therapies for patients with cystic fibrosis.
Launch date
Employees
Market cap
-
Enterprise valuation
€109—164m (Dealroom.co estimates Nov 2014.)
Boulder Colorado (HQ)
Authorizing premium user...